T. Rowe Price Associates
DMK

T. Rowe Price Associates’s DMK Pharmaceuticals Corporation Common Stock DMK Stock Holding History

T. Rowe Price Associates’s Portfolio DMK Stock Details DMK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-1,411
Closed -$346K – 2603
2018
Q3 		$346K Buy
1,411
+414
+42% +$98K ﹤0.01% 2302
2018
Q2 		$223K Hold
997
– – ﹤0.01% 2426
2018
Q1 		$244K Sell
997
-416
-29% -$109K ﹤0.01% 2362
2017
Q4 		$435K Buy
+1,413
New +$465K ﹤0.01% 2140

Other funds holding DMK

First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BA
Bard Associates Chicago, Illinois $398M AUM 54.32% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
LCM
Leisure Capital Management Costa Mesa, California $286M AUM 26.75% 1-Year Est. Return

T. Rowe Price Associates's DMK Position: Q4 2018 in Review

T. Rowe Price Associates sold out of DMK Pharmaceuticals Corporation Common Stock (DMK) in Q4 2018, closing a stake of 1,411 shares — an estimated $346K sold.

T. Rowe Price Associates first reported a position in DMK in Q4 2017 and held it in 4 quarters. The position peaked at $435K in Q4 2017. 58 funds tracked by Wall St. Rank hold DMK as of Q4 2018.

  • T. Rowe Price Associates reported no remaining DMK Pharmaceuticals Corporation Common Stock position as of Q4 2018 after selling out during the quarter.
  • T. Rowe Price Associates sold 1,411 DMK Pharmaceuticals Corporation Common Stock shares in Q4 2018, an estimated $346K.
  • T. Rowe Price Associates first reported a position in DMK Pharmaceuticals Corporation Common Stock in Q4 2017 and held it in 4 quarters.
  • T. Rowe Price Associates's DMK Pharmaceuticals Corporation Common Stock position peaked at $435K in Q4 2017.
  • 58 funds tracked by Wall St. Rank held DMK Pharmaceuticals Corporation Common Stock as of Q4 2018.

Based on T. Rowe Price Associates's 13F filing for Q4 2018, filed 14 Feb 2019.